We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Ascending Dose Study (SAD) iv Formulation (2006-006253-27)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00688831
Recruitment Status : Completed
First Posted : June 3, 2008
Last Update Posted : December 2, 2010
Sponsor:
Information provided by:

Study Description
Brief Summary:
The purpose is to study the safety of AZD1305, how AZD1305 is tolerated and how the medication is metabolised by the body (how it is taken up into the body, distributed around the body and disappears from the body

Condition or disease Intervention/treatment Phase
Healthy Drug: AZD1305 Drug: Placebo Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Single-centre, Single-blind, Randomised, Placebo-controlled, Single-dose Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Ascending Intravenous Doses of AZD1305 in Helahty Male Volunteers
Study Start Date : January 2008
Primary Completion Date : May 2008
Study Completion Date : May 2008
Arms and Interventions

Arm Intervention/treatment
Experimental: A
AZD1305 solution for iv infusion
Drug: AZD1305
Solution for iv infusion , single dose
Placebo Comparator: B
NaCl solution for iv infusion
Drug: Placebo
NaCl solution for iv infusion, single dose


Outcome Measures

Primary Outcome Measures :
  1. Adverse events, ECG variables, vital signs, physical examination, laboratory variables, body temperature and weight [ Time Frame: During the study ]

Secondary Outcome Measures :
  1. Pharmacokinetic variables [ Time Frame: During all dosing visits ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers
  • BIM 19-30 kg/m2

Exclusion Criteria:

  • Potassium outside normal reference values
  • ECG findings outside normal range
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00688831


Locations
Sweden
Research Site
Uppsala, Sweden
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Helen Lunde, MD AstraZeneca R&D Mölndal, Sweden
Principal Investigator: Marianne Hartford, MD, PhD AstraZeneca, Clinical Pharmacology Unit, Sahlgrenska University Hospital, Göeborg, Sweden
More Information

Responsible Party: Helen Lunde, MD, Medical Science Director, Emerging Arrythmias & Lipids, AstraZeneca
ClinicalTrials.gov Identifier: NCT00688831     History of Changes
Other Study ID Numbers: D3190C00002
First Posted: June 3, 2008    Key Record Dates
Last Update Posted: December 2, 2010
Last Verified: December 2010

Keywords provided by AstraZeneca:
AZD1305
SAD
safety
pharmcokinetics
Safety and tolerability

Additional relevant MeSH terms:
Pharmaceutical Solutions